Medscape InDiscussion: Lung Cancer Medscape

Drs Jacob Sands and Julia Rotow discuss the latest breakthroughs in lung cancer treatment, including targeted therapy options, toxicities, and diagnostic technology.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/999027). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Young Adults and Lung Cancer: Testing and Treatment Options for a Population That Does Not Qualify for Screening https://www.medscape.com/viewarticle/984258
EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/34127383/
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/29151359/
Osimertinib With/Without Platinum-Based Chemotherapy as First-Line Treatment in Patients With EGFRm Advanced NSCLC (FLAURA2). 2023 World Conference on Lung Cancer. Abstract PL03.13. https://www.sciencedirect.com/science/article/abs/pii/S1556086423008110
MARIPOSA: Phase 3 Study of First-Line Amivantamab + Lazertinib Versus Osimertinib in EGFR-Mutant Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/34911336/
Discovery of Amivantamab (JNJ-61186372), a Bispecific Antibody Targeting EGFR and MET https://pubmed.ncbi.nlm.nih.gov/33839159/
Amivantamab Plus Chemotherapy With and Without Lazertinib in EGFR-Mutant Advanced NSCLC After Disease Progression on Osimertinib: Primary Results From the Phase III MARIPOSA-2 Study https://pubmed.ncbi.nlm.nih.gov/37879444/
Consensus Recommendations for Optimizing Biomarker Testing to Identify and Treat Advanced EGFR-Mutated Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/33380864/
Next Generation Sequencing Technology in Lung Cancer Diagnosis https://pubmed.ncbi.nlm.nih.gov/34571741/
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/32955177/
Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress https://pubmed.ncbi.nlm.nih.gov/33558193/
[NCT03456076] A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer. https://clinicaltrials.gov/study/NCT03456076
Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies https://pubmed.ncbi.nlm.nih.gov/33172113/
Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2302299
NCCN Guidelines: Non-Small Cell Lung Cancer https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450
Amivantamab Plus Chemotherapy in NSCLC With EGFR Exon 20 Insertions https://pubmed.ncbi.nlm.nih.gov/37870976/

Drs Jacob Sands and Donald L. Rosenstein discuss the psychology of lung cancer and how to effectively communicate with patients about diagnosis, treatment, and expectations.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/999028). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Lung Cancer https://www.medscape.com/resource/lungcancer/rc-lungcancer2
The Flourishing Scholarship of Psychosocial Oncology Viewed Across 30 Years Through the Lens of This Journal, Psycho-Oncology https://pubmed.ncbi.nlm.nih.gov/35396891/
Living With and Beyond Cancer: Psychosocial and Psychological Support for Patients From Diagnosis Through Survivorship https://www.medscape.com/viewarticle/985096
"Scanxiety" and a Sense of Control: The Perspective of Lung Cancer Survivors and Their Caregivers on Follow-up - A Qualitative Study https://pubmed.ncbi.nlm.nih.gov/37069692/
Psychotherapy Alone Versus Collaborative Psychotherapy and Psychiatric Care in the Treatment of Depression and Anxiety in Patients With Cancer: A Naturalistic, Observational Study https://pubmed.ncbi.nlm.nih.gov/37209423/
Creating a Proactive Interdisciplinary Approach to Care: Embedding Oncology Care Coordination Within an Oncology Patient and Family Support Program https://ascopubs.org/doi/10.1200/JCO.2022.40.28_suppl.051
Use of PHQ-9 for Monitoring Patients With Depression in Integrated Primary Care Practices https://pubmed.ncbi.nlm.nih.gov/36693193/
Using Generalized Anxiety Disorder-2 (GAD-2) and GAD-7 in a Primary Care Setting https://pubmed.ncbi.nlm.nih.gov/32582485/
Implementing Collaborative Care for Major Depression in a Cancer Center: An Observational Study Using Mixed-Methods https://pubmed.ncbi.nlm.nih.gov/35305403/

Drs Jacob Sands and Narjust Florez discuss the nuances of treating women with lung cancer, including screening, treatment, and sexual and reproductive health.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/999029). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
The Role of Cultural Humility in Addressing Disparities in Lung Cancer Treatment: How Can Physicians Make a Difference? https://www.medscape.com/viewarticle/969537
Higher Lung Cancer Incidence in Young Women Than Young Men in the United States https://pubmed.ncbi.nlm.nih.gov/29791813/
Sexual Health Assessment in Women With Lung Cancer Study: Sexual Health Assessment in Women With Lung Cancer https://pubmed.ncbi.nlm.nih.gov/37843054/
EGFR Resisters https://egfrcancer.org/
GO2 for Lung Cancer https://go2.org/

Drs Jacob Sands and Benjamin P. Levy discuss antibody-drug conjugates in lung cancer treatment, including differences in efficacy, toxicity profiles, and what the future holds.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999030. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress https://pubmed.ncbi.nlm.nih.gov/37163707/
TROP-2 Directed Antibody-Drug Conjugates (ADCs): The Revolution of Smart Drug Delivery in Advanced Non-Small Cell Lung Cancer (NSCLC) https://pubmed.ncbi.nlm.nih.gov/37230055/
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan https://pubmed.ncbi.nlm.nih.gov/28548889/
Gilead Provides Update on Phase 3 EVOKE-01 Study https://www.gilead.com/news-and-press/press-room/press-releases/2024/1/gilead-provides-update-on-phase-3-evoke-01-study
EVOKE-02: A Phase 2 Study of Sacituzumab Govitecan (SG) Plus Pembrolizumab (Pembro) With or Without Platinum Chemotherapy in First-Line Metastatic Non–Small Cell Lung Cancer (NSCLC) https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.TPS9146
Datopotamab Deruxtecan Met the PFS Endpoint in Previously Treated NSCLC https://dailyreporter.esmo.org/esmo-congress-2023/non-small-cell-lung-cancer/datopotamab-deruxtecan-met-the-pfs-endpoint-in-previously-treated-nsclc
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-Drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells https://pubmed.ncbi.nlm.nih.gov/34413126/
Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial https://pubmed.ncbi.nlm.nih.gov/37694347/
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/36288547/
Press Release: Sanofi Announces End of Program Evaluating Tusamitamab Ravtansine After a 2L NSCLC Phase 3 Trial Did Not Meet a Primary Endpoint https://www.globenewswire.com/news-release/2023/12/21/2799759/0/en/Press-Release-Sanofi-announces-end-of-program-evaluating-tusamitamab-ravtansine-after-a-2L-NSCLC-Phase-3-trial-did-not-meet-a-primary-endpoint.html
Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm? https://pubmed.ncbi.nlm.nih.gov/37370772/
BL-B01D1, a First-in-Class EGFRxHER3 Bispecific Antibody-Drug Conjugate (ADC), in Patients With Locally Advanced or Metastatic Solid Tumor: Results From a First-in-Human Phase 1 Study https://meetings.asco.org/abstracts-presentations/218492

Drs Jacob Sands and Jared Weiss discuss subtypes; ongoing clinical trials; durable, ongoing responses to therapy; and the potential for using the word "cure" in the treatment of small cell lung cancer.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984257). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Immunotherapy and Lung Cancer Treatment https://www.medscape.com/viewarticle/969534
Small Cell Lung Cancer (SCLC) https://emedicine.medscape.com/article/280104-overview
FDA Grants Accelerated Approval to Lurbinectedin for Metastatic Small Cell Lung Cancer https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer
Lurbinectedin as Second-Line Treatment for Patients With Small-Cell Lung Cancer: A Single-Arm, Open-Label, Phase 2 Basket Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30068-1/fulltext
Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer https://ascopubs.org/doi/10.1200/JCO.2006.06.5821
Study of Trilaciclib and Lurbinectidin https://clinicaltrials.gov/ct2/show/NCT05578326
PL02.03 Lurbinectedin/Doxorubicin Versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial https://www.jto.org/article/S1556-0864(21)02453-9/fulltext
Erythropoiesis-Stimulating Agents in Oncology: A Study-Level Meta-Analysis of Survival and Other Safety Outcomes https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816662
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) https://clinicaltrials.gov/ct2/show/NCT05361395
Bispecific T-Cell Engager (BiTE) Antibodies https://reference.medscape.com/drugs/bispecific-t-cell-engager-bite-antibodies

Drs Jacob Sands and Julia Rotow discuss genomic testing, treatment options, and clinical trials for young adults who do not qualify for lung cancer screening.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984258). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Lung Cancer https://www.medscape.com/resource/lungcancer
Lung Cancer in Patients Under the Age of 40 Years https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687453/
Proportion of Never Smokers Among Men and Women With Lung Cancer in 7 US States https://jamanetwork.com/journals/jamaoncology/article-abstract/2773380
What Are the Risks and Benefits of Lung Cancer Screening? https://www.medscape.com/viewarticle/969532
Biomarker Tissue Journey Among Patients With Untreated Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network https://pubmed.ncbi.nlm.nih.gov/35313244/
Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers in the United States https://pubmed.ncbi.nlm.nih.gov/35737912/
Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung Cancer https://jamanetwork.com/journals/jamaoncology/fullarticle/2475482
Biology of Young Lung Cancer Study: The YOUNG LUNG Study https://clinicaltrials.gov/ct2/show/NCT05265429
Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) https://www.clinical-lung-cancer.com/article/S1525-7304(22)00265-0/fulltext
Clinical Utility and Performance of an Ultrarapid Multiplex RNA-Based Assay for Detection of ALK, ROS1, RET, and NTRK1/2/3 Rearrangements and MET Exon 14 Skipping Alterations https://linkinghub.elsevier.com/retrieve/pii/S1525-1578(22)00080-0
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482929/
Immune Checkpoint Inhibitors for Patients With Advanced Lung Cancer and Oncogenic Driver Alterations: Results From the IMMUNOTARGET Registry https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7389252/
Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419340/
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting https://linkinghub.elsevier.com/retrieve/pii/S0012-3692(22)01068-6
Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Induced Hepatic Failure in Lung Cancer Patients: A Study of Signal Mining and Analysis of the FDA Adverse Event Reporting System Database https://pubmed.ncbi.nlm.nih.gov/33768534/
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) https://www.clinicaltrials.gov/ct2/show/NCT03157128